AI-Driven Drugs and Longevity
Charlie Madden@charliemadden
−4.0%
since Oct 2
The idea
I believe AI is compressing the time and cost of drug development, with early payoffs showing up in metabolic health and longevity. The basket's core sits in tools, data, and compute providers who get paid regardless of whose model wins, alongside AI discovery platforms and the big pharma companies positioned to commercialize what they produce. Smaller positions round it out: a GLP-1 and metabolic slice, a peptide manufacturing and delivery layer, and a speculative aging biotech stake, with some cash held back and no single name allowed to dominate.
What it owns
- Every AI drug pipeline needs sequencing, lab instruments, clinical data and chips, so these suppliers get paid regardless of which discovery platforms or drugmakers succeed. · Thermo Fisher ScientificIt sells the instruments, reagents and services every drug developer buys, so it gets paid no matter which AI platform or drugmaker succeeds in the industry., DanaherIt makes the bioprocessing and diagnostics equipment that turns discoveries into manufactured drugs, benefiting from rising biologics manufacturing volumes as AI-found drugs reach production., NVIDIAIt supplies the chips that train and run the biology models that drug discovery platforms depend on, making it a core beneficiary of rising AI compute demand in pharma., Veeva SystemsIt runs the software pharma companies use for trials, regulatory work and sales, the infrastructure layer that any AI-accelerated pipeline still must travel through., IlluminaIts sequencers generate the genomic data that AI drug models learn from, so more AI discovery means rising demand for sequencing volumes and data.30%
- GLP-1 drugs are already extending healthy lifespans by treating obesity and metabolic disease at scale, the first major longevity medicines to reach mass markets. · Eli LillyIt leads the GLP-1 wave with Zepbound and Mounjaro and is developing next-generation versions including oral formulations as the obesity drug market expands., Novo NordiskIt built the GLP-1 market with Ozempic and Wegovy and pairs with Lilly as the other major winner in the expanding obesity and metabolic disease treatment space., Viking TherapeuticsIt is developing obesity candidates that could compete with or outperform the current market leaders, with its case resting on strong clinical trial data.18%
- These companies use AI to design drugs directly, compressing discovery timelines and costs, the purest and highest-upside version of the artificial intelligence bet in drug development. · SchrödingerIt designs drugs using physics simulations and machine learning to compress the time and cost of finding molecules, advancing computed drug candidates into the clinic., Recursion PharmaceuticalsIt runs drug discovery at industrial scale using automated labs and machine learning to map biology faster and cheaper than traditional discovery methods., Tempus AIIt owns one of the largest clinical and genomic datasets and sells AI insights built on top of it, supplying the raw material that AI drug development depends on., AbCellera BiologicsIt uses AI to find antibody drugs for partners, winning if artificial intelligence shortens discovery timelines across the entire drug development stack.17%
- Large drugmakers have the capital and clinical trial machinery to license, scale and commercialize whatever AI discovery platforms produce, and they need new pipelines as patents expire. · MerckIt has the cash and clinical machinery to license and commercialize AI-discovered drugs while it refills its pipeline ahead of patent expirations., AstraZenecaIt has leaned harder into AI discovery partnerships than most large drugmakers, demonstrating how incumbents can adopt these tools to source new pipeline candidates., Johnson & JohnsonIt is a steady acquirer and commercializer of new therapies with a strong pharma pipeline and balance sheet to buy and scale AI-era drug discoveries.15%
- AI now designs peptide drugs directly and the GLP-1 boom has made peptide manufacturing and injectable delivery a production bottleneck across the industry. · Protagonist TherapeuticsIt engineers peptide drugs including oral formulations with partners like Takeda and Johnson & Johnson, advancing a platform approach to peptide drug discovery., West Pharmaceutical ServicesIt makes the stoppers, syringe components and injector parts that every injectable peptide drug requires, a manufacturing bottleneck created by the GLP-1 boom., AltimmuneIt develops peptide drugs for metabolic disease where the GLP-1 opportunity and peptide manufacturing angle overlap, with its case depending on strong obesity trial data.10%
- A small speculative stake in companies working on aging biology itself represents the long tail of the longevity bet, targeting the fundamental causes of aging rather than its symptoms. · BioAge LabsIt uses human aging data to pick metabolic and longevity drug targets, pursuing the longevity idea in its most direct biological form.2%
- Cash7%